Nomura Holdings Inc. Sells 787 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Nomura Holdings Inc. has reduced its stake in IDEXX Laboratories by 12.4%, now holding 5,548 shares valued at $2.33 million after selling 787 shares.
• Analysts have issued varied price targets for IDEXX, with Morgan Stanley raising their target to $765.00, while others maintain bullish ratings including a "buy" from Jefferies at $625.00.
• Insider activity has seen significant stock sales, including a director and executive vice president selling a combined total of over $5 million in shares within the last month.

Nomura Holdings Inc. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,548 shares of the company's stock after selling 787 shares during the quarter. Nomura Holdings Inc.'s holdings in IDEXX Laboratories were worth $2,330,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in IDXX. MorganRosel Wealth Management LLC purchased a new position in IDEXX Laboratories during the first quarter valued at $26,000. Colonial Trust Co SC raised its stake in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares during the last quarter. WPG Advisers LLC purchased a new position in IDEXX Laboratories during the first quarter valued at $37,000. Finally, Bank of Jackson Hole Trust raised its stake in IDEXX Laboratories by 328.6% during the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company's stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded up $2.55 during midday trading on Friday, reaching $642.99. 370,390 shares of the company traded hands, compared to its average volume of 413,114. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The firm has a market capitalization of $51.44 billion, a price-to-earnings ratio of 53.54, a price-to-earnings-growth ratio of 4.16 and a beta of 1.56. The business has a 50 day moving average of $593.22 and a two-hundred day moving average of $507.11.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories's revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent research reports. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. BTIG Research lifted their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. Finally, Morgan Stanley lifted their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.